Site is Being Upgraded

Combinatorial therapy for Myocardial Infarction:  A pharmaceutical mixture encompassing Pyridoxamine (PM, Vit-B6) and Hydralazine (HL)  inhibits DNA damage responses, induces telomerase expression, inhibits telomere shortening, and promotes cardiomyocyte survival after myocardial infarction via up regulation of PNUTS, 17/February/2018, 11.28 pm

Combinatorial therapy for Metastatic cancers: A pharmaceutical mixture encompassing Docosahexaenoic acid (DHA) and Aspirin (ASA)   increases the expression of tumor/metastatic suppressors PTEN and PDCD4, inhibits cell cycle progression, and suppresses migration, invasion and metastasis of cancer cells via up regulation of its target gene, 17/February/2018, 11.22 pm
February 17, 2018
Activation of the PD-1 pathway for Pain therapy: Duloxetine (brand name: Cymbalta) increases the expression of PD-L1, attenuates acutes and chronic pain, and suppresses mechanical and thermal hypersensitivity and inhibits nociceptive neuron excitability via up-regulation of its target gene, 17/February/2017, 11.34 pm
February 17, 2018
Show all

What they say

A recent study from the Institute for Cardiovascular Regeneration, Centre of Molecular Medicine, Frankfurt, Germany shows that “MicroRNA-34a regulates cardiac ageing and function.” This study was published, in the 7 March  2013 issue of of the jounal Nature,  by Prof Dimmler, Boon, and others.


What we say

On the foundation of this interesting finding, Dr L Boominathan PhD, Director-cum-chief Scientist of GBMD, reports that:  Combinatorial therapy for Myocardial Infarction:  A pharmaceutical mixture encompassing Pyridoxamine (PM, Vit-B6) and Hydralazine (HL)  inhibits DNA damage responses, induces telomerase expression, inhibits telomere shortening, and promotes cardiomyocyte survival after myocardial infarction via up regulation of PNUTS

price-300[easy_payment currency=”USD”]


From Significance of the study to Public Health relevance:

Given that: (1)  cardiovascular disease is the leading cause of death worldwide; (2) the raise of death rate, due to cardiovascular disease, has increased from  123 lakhs in 1990 to 173 lakhs in 2013; (3) 85% of people over 80 years are susceptible to cardiovascular diseases;(4) in India, in 2004, 14.6 lakhs deaths (14% of total deaths) were due to ischemic heart disease; (3) the death due to cardiovascular disease is higher in low-to-middle income countries compared to developed countries; (4) the global economic cost spent in the treatment of cardiovascular disease in 2011 was little more than 10 billion US dollars; (5) an alarming number of people, such as 230 lakhs people, will die from cardiovascular diseases each year by 2030, there is an urgent need to find: (i) a way to induce regeneration of cardiomyocytes that were lost in Myocardial patients; (ii) a cheaper alternative to the existing expensive drugs; and (iv) a side-effect-free Natural product-based drug.


From Research Findings to Therapeutic Opportunity

This study provides provides, for the first time, mechanistic insight into how  a pharmaceutical mixture encompassing Pyridoxamine (PM, Vitamin-B6) and Hydralazine (HL) may protect against myocardial infarction.  

Figure 1. Hydralazine (HL) functions as a Cardioprotective agent. Mechanistic insights into how a pharmaceutical mixture encompassing Pyridoxamine (PM, Vit-B6) and Hydralazine (HL)  induces the expression of PNUTS and Telomerase to prevent myocardial infarction and promote Cardiac regeneration/survival

Figure 2. The chemical structure of Pyridoxamine and Hydralazine (HL).  A pharmaceutical mixture encompassing Pyridoxamine (PM, Vit-B6) and Hydralazine (HL)  may function as a cardioprotective agent through induction of PNUTS

 A pharmaceutical mixture(PMHL) encompassing Pyridoxamine (PM, Vit-B6) and Hydralazine (HL), by increasing the expression of its target genes, it may increase the expression of PNUTS (fig.1)Thereby, it may: (1) inhibit DNA damage responses, (2) increase telomerase expression, (3) inhibit telomere shortening; (4) promote cardiomyocyte survival/regeneration; (5) decelerate ageing; and (6) extend life span (fig 1). 

Thus, by treating patients with PMSF, one may prevent ageing-associated (or, stress-associated) decline in cardiac function. Together, this study suggests that pharmacological formulations encompassing “Pyridoxamine (PM, Vit-B6) and Hydralazine (HL)  or their analogs, either alone or  in combination with any of the known compounds that improve myocardial function,”  may be used to improve cardiac function after myocardial infarction (fig. 3).  


Details of the research findings: 

Idea Proposed/Formulated (with experimental evidence) by:

Dr L Boominathan Ph.D.

Terms & Conditions apply http://genomediscovery.org/registration/terms-and-conditions/

Undisclosed mechanistic information: How  a pharmaceutical mixture encompassing Pyridoxamine (PM, Vit-B6) and Hydralazine (HL) increases the expression of PNUTS/Telomerase

Amount: $300#

# Research cooperation

For purchase and payment details, you may reach us at admin@genomediscovery.org


References:

Web:http://genomediscovery.org or http://newbioideas.com/

CitationBoominathan, L.,   Combinatorial therapy for Myocardial Infarction:  A pharmaceutical mixture encompassing Pyridoxamine (PM, Vit-B6) and Hydralazine (HL)  inhibits DNA damage responses, induces telomerase expression, inhibits telomere shortening, and promotes cardiomyocyte survival after myocardial infarction via up regulation of PNUTS, 17/February/2018, 11.27 pm,  Genome-2-Bio-Medicine Discovery center (GBMD), http://genomediscovery.org

Courtesy: When you cite drop us a line at admin@genomediscovery.org

Comments are closed.